Biotech investors had a great deal to be thankful for heading into the Thanksgiving holiday. With just one month to go before biotech closes the curtains on another year, the sector appears to be back on track and stands poised to finish 2015 in positive territory, a performance which is much better than some pundits were predicting when valuations nosedived during August and September as the heated debate over drug prices got into high gear.